Chelonian Conservation And Biology

Vol. 17No.2 (2022) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI:doi.org/10.18011/2022.04(1) 1241-1251

CRITICAL ANALYSIS OF THE ROLE OF PET-CT IN THE EVALUATION OF HEPATIC TUMORS

Nasser Muhanna Alanazi
namalanazi@moh.gov.sa
Ministry of Health, Saudi Arabia

Sara Fahad Alqhtani
salqhateeny@moh.gov.sa
Ministry of Health, Saudi Arabia

Maram Hashem Almuhanna
malmuhanna@moh.gov.sa
Ministry of Health, Saudi Arabia

Ghadeer Abdulrahman Al-Shalail
galshalail@moh.gov.sa
Ministry of Health, Saudi Arabia

Raja Sughayir Ali Alasiri
ralasairy@moh.gov.sa
Ministry of Health, Saudi Arabia

Sharifa Mohammed A Hadi
smhadi@moh.gov.sa
Ministry of Health, Saudi Arabia

Abdullah Awad Alnabani
aalnabani@moh.gov.sa
Ministry of Health, Saudi Arabia

Awad Hindi Alotaibi
awhialotaibi@moh.gov.sa
Ministry of Health, Saudi Arabia

ABSTRACT

This article contains a detailed consideration of PET-CT, which plays a paramount role in evaluating liver tumors. Hematoma, a hepatic tumor involving primary liver cancer and metastatic lesions, has substantial diagnostic and treatment challenges. PET-CT is a hybrid imaging modality that melts together anatomy and function. This imaging machine was discovered to be a gold standard examination tool for assessing hepatic tumors. This investigation covers the clinical utility, weak points, and further prospects of PET-CT, mainly hepatic tumor evaluation methods, which provide a background for physicians who deal with patients with liver cancer.

Keywords: PET-CT, hepatic malignant tumors, liver cancer, metastasis, imaging, diagnosis.

INTRODUCTION

Primary liver cancer and metastatic lesions are the two most frequent types of hepatic tumors diagnosed, and they present various lesions, from liver hemorrhage to malignant fibrous histiocytoma. The precise assessment and grading of these tumors are imperative to provide for the individualized treatment and prognosis of the disease. Although ultrasound, CT, and MRI are typically the imaging modalities of choice in the diagnosis of hepatic lesions, they do have many shortcomings: they are not always distinct in determining whether a lesion is benign or malignant; they are less sensitive in finding small lesions but are most helpful in characterizing liver metastases(Cho et.,al 2020, November).

This technique, known as PET-CT (positron emission tomography-computed tomography), has recently turned out to be a very dynamic imaging tool for the diagnosis of liver tumors. The union of function and the anatomy of the disease in one scanning PET-CT examination provides the patient with a unique comfort in the case of a liver lesions study that is different from others. The PET-CT employs radioactive tracers that help visualize the metabolic activity of the tissue. Consequently, it provides crucial details on the biological nature of hepatic tumors. CT imaging not only supplies anatomical precision but also contains the microstructural information of diseases, which can be helpful in diagnosis.

This paper will discern the significance of PET-CT examination in hepatic tumor determination, examining its clinical application, concerns, and research hurdles. Our goal, therefore, lies in considering the previous literature and published research to draw some conclusions about the advantages and disadvantages of PET-CT in hepatic tumors. In addition, we also intend to determine regions for further improvement and search for new areas of research in the field of hepatic imaging.

Through such investigation, we aspire to improve how PET-CT is evaluated in liver tumors and inform clinicians, based on this outcome, of the best way a PET-CT should be interpreted and used. Ultimately, the main target is the automation of diagnostics, the refinement of treatment planning, and the improvement of patient outcomes associated with hepatic tumors.

BODY

Clinical Applications of PET-CT in Hepatic Tumors:

Three dedicated patient evaluations where PET-CT scans are used are also used to assess hepatic tumors. Its primary function can be determined by differentiating benign from malignant liver abnormalities. PET-CT infuses radiotracers, including FDG, into liver lesions that can be used to assess their metabolic activity. As a rule, malignant tumors (in most cases) demonstrate an increased glucose metabolism, leading to the fact that FDG activity surpasses regular benign lesions. CT-PET information, which is given to doctors, indicates benign lesions with hemangiomas or focal nodular hyperplasia and reveals malignant lesions, which are, for example, hepatocellular carcinoma (HCC) and metastatic liver tumors(Cho et.,al 2020, November).

Apart from that, F-18 PET-CT is an indispensable method of hepatic tumor staging, especially in identifying extrahepatic tumor metastases. HCC and metastatic liver tumors to distant places like lung, bone, or lymph nodes by the end of the following sentence. The localization of metastasis by PET-CT is delivered to the clinicians for treatment options and future life projections. PET-CT plays a further role in tracking treatment results in patients receiving therapy for liver tumors. For diagnosing liver lesions, sequential FDG uptake of the tumor tissue has been used to forecast the response to treatment or the progression to a lesser situation, which makes treatment adjustments timelier.

Diagnostic Accuracy and Comparison with Other Imaging Modalities

Numerous trials have been performed on PET-CT diagnosis compared with other imaging methods, improving the accuracy of hepatic tumor assessment. A meta-analysis by Li et al. showed that the numbers were (89%) sensitive and specific (86%) in detecting HCC compared to contrast-enhanced MRI and CT in some instances. Despite this, it should be noted that PET-CT has difficulty detecting lesions at the moment when their sizes are less than 1 cm. This is especially noticeable in people with liver cirrhosis, which adds flat FDG uptake to small lesions.

Suppose the PET/CT imaging technique is compared to routine multi-parametric MRI (MP-MRI) with a Gd-EOB-DTPA contrast agent. In that case, the diagnostic accuracy for staging hepatic metastases will be comparable. There are pros and cons to both diagnostic tools, with PET-CT having the ability to pinpoint the metabolic activity of tumors and MRI boasting superior soft tissue contrast as well as hepatobiliary imaging. The decision of whether PET-CT or MR imaging is the right approach will depend on your clinical scenario and the availability of resources, such as the type of case and patient-specific characteristics.

Imaging Modality	Pros	Cons	Cost[25, 26]
X-Ray	Cheap	Low sensitivity, delayed findings	~$50-100
US	Cheap, useful in children and sickle cell patients	Low sensitivity, difficult interpretation	~$100-200
Bone Scintigraphy	High sensitivity	Poor specificity	~$150-600
CT	Useful for bony architecture, necrotic bone in chronic osteomyelitis, can guide biopsy	Increased cost and radiation exposure	~400-700
MRI	Highly specific for both acute and chronic osteomyelitis	High cost	~$700-1200
PET	Highly specific	High cost, limited availability	~$1000-2000

Impact on Treatment Planning

Liver tumors are one of the most challenging cancers to deal with, and it is in this area that PET-CT seems to illuminate pathways for treatment. Performing a PET-CT scan on those with HCC is beneficial in helping the doctors choose the best treatment options for them, which may include surgical resection, liver transplantation, local therapies (radiofrequency ablation, transarterial chemoembolization), or systemic therapy. Due to the correct HCC staging and detection of extrahepatic metastases by PET-CT imaging, the physician will be guided in treatment decisions and the patient's prognostic adjustment(Cho et.,al 2020, November).

In the case of metastatic liver tumors, PET-CT allows the tissue biopsy to be chosen with the optimal selection of systemic therapies using tumor biology and the tumor's metabolic burden. The PET-CT can assist in picking out patients with a limited spread that can be good candidates for complete-oriented local therapies such as surgical resection or stereotactic body radiation therapy (SBRT). Consequently, PET-CT aids clinical staff in therapeutic response tracking and reacting to the changing situation by adapting the therapeutic strategy towards a better response.

Limitations of PET-CT in Hepatic Tumor Evaluation

While PET-CT scanning delivers some specifics in evaluating hepatic tumors, this imaging technique also has some underlying flaws that must be considered. A funny point uncovered here is the lower spatial resolution of PET imaging compared to CT or MRI, which can potentially impact the detection of small lesions, even in the liver. In addition to this other process, which involves the physiological PET-CT uptake by normal liver parenchyma and benign lesions such as hemangiomas, which leads to false positives and reduces PET-CT specificity in the diagnosis of hepatic tumors.

	Strengths	Weaknesses	Opportunities
CT scan	• Widely available • Easily standardised • Low cost • Fast acquisition • Quantitative assessments (Hounsfield unit) • Ability to characterise bone disease into the spectrum between sclerotic and lytic • Soft tissue and lytic bone metastasis detection and response assessments • Incorporated into clinical practice and trial guidelines	• Does not directly evaluate malignant bone disease when soft tissue is absent • Radiation exposure • Limited local disease evaluations • Subcentimetre nodal characterisation • Cannot visualise infiltrative (nonsclerotic) bone disease • CT "flare" response • Inability to diagnose response/progression in sclerotic bone metastases	• Complementary to PET or whole-body MRI information • Sclerotic change in nonsclerotic lesions as potential response parameter • Lung metastases detection • Lytic vs nonlytic bone metastases subclassification
Bone scan	• Widely available • Easily standardised • Low cost • Incorporated into clinical practice and trial guidelines	• Does not directly evaluate malignant bone disease; reactive osteoblastic uptake only • Longest examination times • Pre- and postexamination care precautions • Radiation exposure to patients and public due to longer half-life of technetium Tc 99m • No ability to assess soft tissue disease • Lower sensitivity and specificity than CT/MRI • Bone scan flare response • No positive benefit criteria (progression only)	• Improved test performance by addition of SPECT/CT capability Development of bone scan index as prognostic biomarker
Sodium fluoride PET/CT	• High sensitivity and relatively good specificity for bone metastases (CT component adds specificity) Medium-length examination times	• Does not directly evaluate malignant bone disease; reactive osteoblastic uptake only • Limited tracer availability • Expensive • Multiple sources of radiation exposure (CT scans and radiotracer) • Some postexamination care precautions (not burdensome) • Limited ability to assess soft tissue disease related to the lower quality of the CT component; used for attenuation correction • Flare response phenomenon • No positive benefit criteria (progression only)	• Development of NaF tumour volume index as prognostic biomarker
Choline PET/CT	• Directly evaluates malignant bone marrow disease • High sensitivity and relatively good specificity for detection of bone and soft tissue metastases • Ability to assess response of bone and soft tissue disease • Objective response parameters (SUV) Medium-length examination times	• Limited tracer availability • Expensive • Multiple sources of radiation exposure (CT scans and 18F-CH radiotracer, less so for 11C-CH due to shorter half-life) • Some postexamination care precautions (not burdensome) • Potential to be influenced by bone marrow–stimulating factors • Inability to accurately assess liver and urinary lesions	• Development of SUV as a potential response biomarker • Development of tumour load as a prognostic biomarker
Whole-body MRI	• Directly evaluates malignant bone marrow disease • Potential wide availability Lack of radiation • Flexible, adaptable imaging (possible to tailor examinations according to disease location) • Ability to detect and assess response of bone and soft tissue disease including the prostate, nodes, and viscera • Objective response parameters (size, volume, and ADC measurements)	• Competing demands for MRI resource • Scanner-dependent performance • Longer acquisition time • Susceptible to artefacts • Subcentimetre nodal and lung metastases detection and characterisation ability • Influenced by bone marrow–stimulating factors and blood transfusions • Limited radiologic expertise in some aspects of image analysis • Data analysis challenges • Higher cost (equal to combined bone and CT scans) and reimbursement challenges	• Radiation-free long-term follow-up • Surgical planning • Skeletal event detection (spinal cord compression, critical fractures) • "One stop-shop": bone and soft tissue disease detection and response assessments

(Yamashigeet.,al 2021).

CONCLUSION

Overall, PET-CT is a superior imaging method for the evaluation of hepatic tumors, as it not only provides functional and anatomical information that cannot be obtained by the conventional modality but also contributes to the early detection, localization, and differentiation of hepatic tumors. Image-guided therapy and the differentiation of lesions, the staging of conditions, treatment planning, and response assessment bring diverse clinical applications. Although the PET-CT technique has advantages such as high sensitivity and robustness, it still has limitations like less spatial resolution and anatomical uptake, which could severely affect the diagnostic accuracy of the technique. The innovative aspect of PET-CT trials for tumor monitoring of the liver lies in the improvement of the radiotracers, the evolution of technology, and the combination of artificial intelligence algorithms. PET-CT technology will remain a significant player in hepatic mass management because of the continuous scientific alternative discoveries and technological advancements outlined above. This means that PET-CT technology will lead to best practices, including quality patient outcomes and personalized treatments.

Recommendation

Integration into Multimodal Imaging Protocols: Integration into Multimodal Imaging Protocols:

The implementation of mutual integration in multimodal imaging is one of the primary suggestions for optimizing the role of PET-CT in the evaluation of liver cancer. As PET-CT could be used together with conventional imaging modalities like ultrasound, CT, and MRI, whose primary purpose is to find the tumor or lesion, PET-CT can provide more accurate and detailed information about the metabolic and functional function of the liver that enhances assessment. Integrating PET-CT into multimodal imaging approaches that target liver lesion exploration would improve the level of certainty of the lesion confirmation in cases where the conventional imaging results are discordant or inconclusive, and advanced methods are required. This enables physicians to better assess the lesion character, staging, and treatment plan for individual patients, with the hope of generating the possibility of better patient care.

Considerations in Treatment Planning:

Apart from this, PET-CT findings are used in decisions for patients with hepatic tumors during therapy planning. PET-CT can modify treatment options by showing some diagnoses and helping doctors choose among existing therapeutic modalities, including surgeries, liver transplantation, locoregional therapies (including radiofrequency ablation and transarterial chemoembolization), and systemic therapies. The metabolic information from PET-CT helps to, among other things, characterize lesions, identify other metastases that are away from the liver, and evaluate the responses to treatment. However, we should admit that PET-CT has limitations and possible adverse effects, such as false positive images and benign lesion uptake in physiological settings. One should also be able to interpret these findings using clinical judgment.

Standardization of Interpretation Criteria:

There is a pressing need for standardized interpretive criteria and reporting guidelines for PET-CT in the appraisal of liver neoplasms so medical practitioners will have uniformity across different institutions for consistency and reliability. Introducing criteria for uniform interpretations of lesions, including SUV and qualitative assessment criteria, would help observers gain agreement and reduce the variability of their reporting results. Also, the standardized reporting templates should include the mandatory elements, including lesion size, location, metabolic activity, and potential bleeding, which will increase the possibility of diagnostic success. Establishing unified interpretation criteria for PET-CT findings and reporting guidelines is possible to help the clinical staff make assured treatment decisions that may improve patient treatment and management.

Cost-effectiveness Analysis

Because cost-effectiveness analysis is a critical component of medical technology assessment, the economic impact of PET-CT in evaluating hepatic tumors needs to be established, and its use in clinical practice should be justified. Though PET-CT provides many outstanding diagnostic issues, like better lesion identification and characterization, the cost aspect can be an important factor that may hinder its wide application. As a cost-effectiveness tool, the incremental benefits and costs are assessed for using PET-CT instead of the traditional imaging modalities that institutions currently use(Yamashigeet.,al 2021). Parameters, including diagnostic accuracy, treatment impact, and effectiveness, as well as patients and healthcare resource outcomes, are taken into account when a cost-effectiveness model is created. A thorough assessment of the economic impact of PET-CT by healthcare decision-makers can close the gap between the limited resources deployed to the healthcare sector and the maximization of problems faced by patients.

Future Directions

Advancements in Radiotracer Development

The area of improvement in the use of PET-CT for hepatic tumor evaluations in the future is getting more advancements in radiotracer development. PET radiotracers then demonstrate great significance in the PET examination by localizing the particular biological reactions related to liver cancer. PET-CT has been strengthened on a regular basis by studying new radiotracers that can better depict a variety of tumor characteristics, including metabolism, proliferation, and receptor expression. These radiotracers are expected to increase the precision of PET-CT. Such an achievement could help to get things straight between doctors when needed to determine whether a lesion is benign or cancerous, tell the real significance of a tumor, and predict treatment outcomes, thus providing a more individualized approach and higher effectiveness.

Integration of Artificial Intelligence:

The integration of AI algorithms for image analysis and interpretation is another significant future direction that can be realized for surgical assistance. AI-powered methods, such as machine learning and artificial neural network algorithms, have proven to be capable of examining large datasets of imaging data quickly and identifying the necessary information for clinical purposes. AI algorithms will be able to detect lesions, segment them, and characterize them in PET-CT, resulting in improved accuracy and image interpretation processes. This way, the clinicians can boost their diagnostic skills and then choose the right line of treatment graciously based on the PET-CT findings, ultimately resulting in patients recovering from their illness(Parihar et.,al 2023).

Exploration of Theranostic Approaches:

The theranostic strategy, which involves combining diagnostic imaging with targeted radionuclide therapy, is thus another type of drug therapy that waits to be utilized for the management of hepatic carcinoma. Through PET imaging, the abnormal activities of tumors that align with specific molecular targets and biomarkers can be identified so that clinical doctors can select suitable drug agents and customized treatment plans for patients depending on their specific conditions. Theranostics can serve as diagnostic agents to gauge key tumor parameters while having therapeutic efficacy by specifically using radiation to kill cancerous cells. This strategy provides the opportunity for even precision and individualized administration of methods that could reduce systemic toxicity and, on the other hand, increase therapeutic benefits. The novelty of Theranostics approaches in clinical trials presents itself to research by evaluating their safety, efficacy, and clinical value for cancer patients.

Clinical Trials and Validation Studies:

In order to finalize the study of the likelihood of clinical application, diagnostic usefulness, and impact on therapeutic outcomes of PET-CT in the management of hepatic cancer, it is important to conduct large-scale clinical trials and validation studies. Research that follows the cases of patients whose diagnoses are made with PET-CT and those made with conventional imaging methods, along with histopathological evaluation of the tumor tissue, would help determine the place of PET-CT in clinical practice. Another type of validation study is the study of the reproducibility and reliability of CT-PET findings among different patient populations and healthcare settings, which is a further step in making this technique acceptable and integrated into the care guidelines of clinics(Abdelhalimet.,al 2020). Collaborative efforts among researchers, clinicians, industrial partners, and regulatory partners should be continued to push through innovation, validation of findings, and utilizing research evidence to improve hepatic tumor imaging and management practice.

REFERENCE

Abdelhalim, H., Houseni, M., Elsakhawy, M., AbdElbary, N., &Elabd, O. (2020). Role of 18F-FDG PET-CT in initial staging of hepatocellular carcinoma and its impact on changing clinical decision. *Egyptian Liver Journal*, *10*, 1-4.https://link.springer.com/article/10.1186/s43066-019-0012-9

Akin, E. A., Qazi, Z. N., Osman, M., &Zeman, R. K. (2020). Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. *Abdominal Radiology*, *45*, 1018-1035.https://link.springer.com/article/10.1007/s00261-020-02447-0

Rajamohan, N., Khasawneh, H., Singh, A., Suman, G., Johnson, G. B., Majumder, S., ...&Goenka, A. H. (2022). PET/CT and PET/MRI in neuroendocrine neoplasms. *Abdominal Radiology*, *47*(12), 4058-4072.https://link.springer.com/article/10.1007/s00261-022-03516-2

Howard, B. A., & Wong, T. Z. (2021). 18F-FDG-PET/CT imaging for gastrointestinal malignancies. *Radiologic Clinics*, *59*(5), 737-753.https://www.radiologic.theclinics.com/article/S0033-8389(21)00075-0/abstract

Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023). FDG PET/CT–based Response Assessment in Malignancies. *Radiographics*, *43*(4), e220122.https://pubs.rsna.org/doi/abs/10.1148/rg.220122

ZirakchianZadeh, M. (2023). PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on 18F-FDG. *Clinical & Experimental Metastasis*, *40*(6), 465-491.https://link.springer.com/article/10.1007/s10585-023-10231-9

Yamashige, D., Kawamura, Y., Kobayashi, M., Shindoh, J., Kobayashi, Y., Okubo, S., ...&Kumada, H. (2021). Potential and clinical significance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating liver cancer response to lenvatinib treatment. *Oncology*, *99*(3), 169-176.https://karger.com/ocl/article/99/3/169/239380

Barat, M., Guegan-Bart, S., Cottereau, A. S., Guillo, E., Hoeffel, C., Barret, M., ...&Soyer, P. (2021). CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies. *Abdominal Radiology*, *46*, 2219-2235.https://link.springer.com/article/10.1007/s00261-020-02837-4

Bijlstra, O. D., Boreel, M. M., van Mossel, S., Burgmans, M. C., Kapiteijn, E. H., Oprea-Lager, D. E., ... & de Geus-Oei, L. F. (2022). The value of 18F-FDG-PET-CT imaging in treatment evaluation of colorectal liver metastases: a systematic review. *Diagnostics*, *12*(3), 715.https://www.mdpi.com/2075-4418/12/3/715

Cho, S. Y., Huff, D. T., Jeraj, R., & Albertini, M. R. (2020, November). FDG PET/CT for assessment of immune therapy: opportunities and understanding pitfalls. In *Seminars in nuclear medicine* (Vol. 50, No. 6, pp. 518-531). WB Saunders.https://www.sciencedirect.com/science/article/pii/S0001299820300672

Şahin, E., Elboğa, U., Çelen, Y. Z., Sever, Ö. N., Çayırlı, Y. B., &Çimen, U. (2021). Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. *European Journal of Radiology*, *142*, 109867.https://www.sciencedirect.com/science/article/pii/S0720048X2100348X

Zhou, N., Meng, X., Zhang, Y., Yu, B., Yuan, J., Yu, J., ...& Yang, Z. (2021). Diagnostic value of delayed PET/MR in liver metastasis in comparison with PET/CT. *Frontiers in oncology*, *11*, 717687.https://www.frontiersin.org/articles/10.3389/fonc.2021.717687/full

Albano, D., Durmo, R., Treglia, G., Giubbini, R., &Bertagna, F. (2020). 18F-FDG PET/CT or PET role in MALT lymphoma: an open issue not yet solved—a critical review. *Clinical Lymphoma Myeloma and Leukemia*, *20*(3), 137-146.https://www.sciencedirect.com/science/article/pii/S2152265019320336

Nak, D., Küçük, N. Ö., Çelebioğlu, E. C., Bilgiç, M. S., Hayme, S., &Kır, K. M. (2022). The Role of 18F-FLT PET/CT in Assessing Early Response to TransarterialRadioembolization and Chemoembolization in Patients with Primary and Metastatic Liver Tumors. *Molecular Imaging and Radionuclide Therapy*, *31*(3), 207.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586006/

Marchetti, L., Perrucci, L., Pellegrino, F., Baroni, L., Merlo, A., Tilli, M., ...&Giganti, M. (2021). Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study. *Journal of Nuclear Medicine*, *62*(10), 1372-1379.https://jnm.snmjournals.org/content/62/10/1372.abstract

Casadaban, L. C., Catalano, P. J., Lee, L. K., Hyun, H., Tuncali, K., Gerbaudo, V. H., &Shyn, P. B. (2021). Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study. *European journal of nuclear medicine and molecular imaging*, *48*, 2914-2924.https://link.springer.com/article/10.1007/s00259-021-05206-5

Shi, X., Xing, H., Yang, X., Li, F., Yao, S., Congwei, J., ...& Li, X. (2021). Comparison of PET imaging of activated fibroblasts and 18 F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. *European Journal of Nuclear Medicine and Molecular Imaging*, *48*, 1593-1603.https://link.springer.com/article/10.1007/s00259-020-05070-9

Lyu, Q., Lin, D., Tang, M., Liu, D., Zhang, J., Wang, Y., ...& Li, S. (2022). 18F-FDG PET/CT and MR imaging features of liver metastases in gastrointestinal stromal tumors: a cross-sectional analysis. *Annals of Translational Medicine*, *10*(22).https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761173/

Kim, N. H., Lee, S. R., Kim, Y. H., & Kim, H. J. (2020). Diagnostic performance and prognostic relevance of FDG positron emission tomography/computed tomography for patients with extrahepatic cholangiocarcinoma. *Korean Journal of Radiology*, *21*(12), 1355.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689144/

Tahtabasi, M., Erturk, S. M., &Basak, M. (2021). Comparison of MRI and 18F-FDG PET/CT in the Liver Metastases of Gastrointestinal and Pancreaticobiliary Tumors. *ŞişliEtfalHastanesi Tip Bülteni*, *55*(1), 12-17.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=sislietfaltip&ppdf=2&plng=tur&un=SETB-80270

Mayerhoefer, M. E., Prosch, H., Beer, L., Tamandl, D., Beyer, T., Hoeller, C., ...&Haug, A. R. (2020). PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. *European journal of nuclear medicine and molecular imaging*, *47*, 51-60.https://link.springer.com/article/10.1007/s00259-019-04452-y

Koppula, B. R., Fine, G. C., Salem, A. E., Covington, M. F., Wiggins, R. H., Hoffman, J. M., & Morton, K. A. (2022). PET-CT in clinical adult oncology: III. gastrointestinal malignancies. *Cancers*, *14*(11), 2668.https://www.mdpi.com/2072-6694/14/11/2668

Unterrainer, M., Ruzicka, M., Fabritius, M. P., Mittlmeier, L. M., Winkelmann, M., Rübenthaler, J., ...&Cyran, C. C. (2020). PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. *European radiology experimental*, *4*, 1-13.https://link.springer.com/article/10.1186/s41747-020-00190-1

Momodu, J. I., &Vangu, M. D. T. (2022). F-18 Fluoro-2-Deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Melanoma: Normal

Variants, Pitfalls, and Artifacts. *Frontiers in Nuclear Medicine*, *2*, 835404.https://www.frontiersin.org/articles/10.3389/fnume.2022.835404/full

Van de Wiele, C., Juanito, G., Vander, B. K., Lawal, I., Sathekge, M., Maes, A., & De Spiegeleer, B. (2021, November). Practical considerations when interpreting FDG PET/CT imaging for staging and treatment response assessment in melanoma patients. In *Seminars in Nuclear Medicine* (Vol. 51, No. 6, pp. 544-553). WB Saunders.https://www.sciencedirect.com/science/article/pii/S0001299821000428